LYNKUET

This brand name is authorized in United States. It is also authorized in Austria, Estonia, Italy, Lithuania.

Active ingredients

The drug LYNKUET contains one active pharmaceutical ingredient (API):

1	Elinzanetant UNII NZW2BOW35N - ELINZANETANT
	Elinzanetant is a non-hormonal, selective neurokinin 1 (NK-1) and 3 (NK-3) receptors antagonist. It blocks NK-1 and NK-3 receptors signalling on kisspeptin/neurokinin B/dynorphin (KNDy) neurons, which is postulated to normalise neuronal activity involved in thermo- and sleep regulation.
	Read more about Elinzanetant

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LYNKUET Soft capsule	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
G02CX07		G Genito urinary system and sex hormones → G02 Other gynecologicals → G02C Other gynecologicals → G02CX Other gynecologicals
Discover more medicines within G02CX07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3137217, 3137262, 3137273
IT	Agenzia del Farmaco	052683012, 052683024, 052683036
LT	Valstybinė vaistų kontrolės tarnyba	1105316, 1105317, 1105318
US	FDA, National Drug Code	50419-475